ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 743

Impact of Detect on Right Heart Catheterization Referral and Results; Data from a Prospective, Unselected, Systemic Sclerosis Cohort

Anna-Maria Hoffmann-Vold1, Håvard Fretheim2, Anders Heiervang Tennøe2, Oyvind Midtvedt2, Torhild Garen2, Einar Gude2, Arne K Andreassen2 and Øyvind Molberg2, 1Division of Rheumatology, Oslo University Hospital, Oslo, Norway, 2Oslo University Hospital, Oslo, Norway

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cardiovascular disease, Clinical practice, pulmonary complications and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The DETECT calculator has been freely available as a tool for earlier detection and diagnosis of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) since 2014. Here, we aimed to evaluate its impact on PAH incidence rates, risk profile and functional class (FC) of patients at time of PAH diagnosis.

Methods: The study cohort included all patients in the prospective Oslo University Hospital (OUH) SSc cohort who performed an incident right heart catheterization (RHC) from 2009 and onwards. We grouped the patients in an early cohort with RHC conducted in 2009-2013, and a DETECT cohort with RHC from 2014-17. PH diagnosis was made by an experienced cardiologist according to the updated ESC guidelines with mean (m) PAP ≥ 25 mmHg measured by RHC and borderline PH with a mPAP >19mmHg. Pre and post capillary PHT was defined by PCW above or below 15 mmHg. Risk stratification at time of diagnosis was done using the low, intermediate and high risk grouping system suggested by ESC in 2016. Patients with ≥ 1 parameter of poor prognosis were considered at high risk and with ≥ 1 parameter of intermediate prognosis, at intermediate risk.

Results: An incident RHC was available in 161 patients, 77 from the early cohort and 84 from the DETECT cohort.  Clinical and demographic characteristics are shown in Table 1. Absolute numbers of RHC, PAH and borderline PH cases in the years 2009-2017 are shown in Figure 1. At the time of PAH diagnosis, 27% of the DETECT cohort were in the low risk group compared to 19% in the early cohort, while 27% and 47% respectively belonged  in the high risk groups (p-value 0.219) (Figure 2). We also observed a trend towards lower functional class in the DETECT cohort (Figure 2).

Conclusion: We show that the number of new PAH cases per year has been stable since 2009, with no apparent change following the introduction of the DETECT algorithm. From 2014 and onwards, we observed a, not significant, increase in amount of newly diagnosed PAH cases with low risk group, and better functional class status. The total number of RHC increased from 2014 and onwards, with a concomitant increase in the number of borderline PH cases.

 

Table 1: Demographics and clinical characteristics

 

Total cohort

(n=161)

2009-13

(n=77)

2014-17

(n=84)

p-value

Age at RHC, yrs (SD)

61 (11.8)

59.6 (12.2)

62.4 (11.3)

0.137

Time onset to RHC, yrs (SD)

6.6 (8.2)

6.3 (8.3)

6.9 (8.1)

0.634

Follow-up, yrs (SD)

2.9 (2.4)

4.6 (2.2)

1.2 (0.8)

<0.001

Females, no (%)

126 (78.8)

60 (77.9)

66 (78.6)

0.582

Ever smoker, no (%)

67 (41.9)

28 (36.4)

39 (46.4)

0.064

Limited cutaneous SSc, no (%)

125 (78.1)

63 (81.8)

63 (75)

0.502

Anti-centromere Ab, no (%)

78 (48.8)

37 (48.1)

34 (40.5)

0.848

Digital ulcers, n (%)

61 (38.1)

31 (40.3)

30 (35.7)

0.911

Scleroderma renal crisis, n (%)

7 (4.4)

4 (5.2)

3 (3.6)

0.562

Baseline modified Rodnan skin score

9.9 (8.8)

9.8 (10.5)

9.9 (9.8)

0.934

Pulmonary hypertension, n (%)

65 (40.6)

35 (45.5)

30 (35.7)

<0.001

PAH total, n (%)

31 (19.4)

16 (20.8)

15 (17.9)

 

PH-ILD, n (%)

20 (12.5)

14 (18.2)

6 (7.1)

 

Post capillary PH, n (%)

14 (8.8)

5 (6.5)

9 (10.7)

 

Borderline PH, n (%)

38 (23.8)

19 (24.7)

27 (32.1)

 

No PH, n (%)

57 (35.6)

23 (29.9)

27 (32.1)

 

Myocardial infarction, n (%)

14 (8.8)

8 (10.4)

6 (7.1)

0.557

Angina pectoris, n (%)

14 (10.1)

9 (11.7)

5 (6)

0.414

 

Figure 1: Frequency of conducted incident RHC, PAH, borderline PH and no PH

 

Figure 2: Risk stratification and functional class


Disclosure: A. M. Hoffmann-Vold, None; H. Fretheim, None; A. Heiervang Tennøe, None; O. Midtvedt, None; T. Garen, None; E. Gude, None; A. K. Andreassen, None; Ø. Molberg, None.

To cite this abstract in AMA style:

Hoffmann-Vold AM, Fretheim H, Heiervang Tennøe A, Midtvedt O, Garen T, Gude E, Andreassen AK, Molberg Ø. Impact of Detect on Right Heart Catheterization Referral and Results; Data from a Prospective, Unselected, Systemic Sclerosis Cohort [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/impact-of-detect-on-right-heart-catheterization-referral-and-results-data-from-a-prospective-unselected-systemic-sclerosis-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-detect-on-right-heart-catheterization-referral-and-results-data-from-a-prospective-unselected-systemic-sclerosis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology